Abner M. Mhashilkar

Dr. Mhashilkar focuses on the Stem Cell industry and other biotechnology industries at Toucan Capital.
He has Medical Research and Development experience with emphasis on Regenerative Medicine, including Stem Cell Banking and its Clinical applications, Gene therapy using viral and non-viral vectors, and Engineered-Antibody therapeutics.
Prior to joining Toucan, Dr. Mhashilkar held a Group Leader position at Athersys Inc., and was engaged in their research programs in cardiovascular disease, process development and manufacturing of bone marrow derived adult stem cells.
Before coming to Athersys, Dr. Mhashilkar worked in capacities of Scientific Director, Consultant and Research Manager in different Biotechnology companies.
Dr. Mhashilkar received his M.Sc.
from Bombay University, India, and trained there as Mycologist and Medical Microbiologist.
He obtained his second M.Sc.
in Biochemistry/Life Sciences from Weizmann Institute of Sciences, Rehovot, Israel followed by his Ph.D.
in Biochemistry/Molecular Biology from University of Waterloo, Canada.
Dr. Mhashilkar received post-doctoral training in Antibody Engineering, HIV and Retroviral vectors at Dana-Farber Cancer Institute/Harvard Medical School, Boston.